Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Axsome Therapeutics

Reata Pharmaceuticals

Investors may want to keep an eye on biotech growth stocks, which are typically associated with the risk-on trade. Case in point: The sector ran up in January, but when the broader-market rally fizzled, it sold off hard as investors sought safer havens.

The 3 Best Growth Stocks to Buy in the Biotech Sector

Legend Biotech

Roivant Sciences Ltd

Beam Therapeutics

Editas Medicine

Intellia Therapeutics

Ultragenyx Pharmaceutical

While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy undergird myriad therapeutic advancements. For patients, they represent hope for a positive outcome.

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

Here is how CRISPR Therapeutics AG (CRSP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

Is CRISPR Therapeutics (CRSP) Stock Outpacing Its Medical Peers This Year?

ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Directors after nearly a decade of service.

CRISPR Therapeutics Announces Departure of Board Member

Vertex Pharmaceuticals

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D).

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

CRISPR has some important elements in common with vaccine giant Moderna. And the company is heading for an important moment in its growth story.

Could CRISPR Therapeutics Become the Next Moderna?

CRISPR's gene editing process could change how we treat disease. The biotech's first potential product, exa-cel, could soon hit the market.

Could This Stock Become the Tesla of Its Industry?

Global X Genomics & Biotechnology ETF

CRISPR could revolutionize the way we treat thousands of diseases. Currently, there are about 7,000 caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wrong amount of genetic material, as noted by the Cleveland Clinic.

The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket

CRISPR Therapeutics is closing in on an important regulatory event. The FDA is considering its potential gene-editing therapy for sickle cell disease.

This Cathie Wood Stock Could Nearly Double, According to Wall Street

CRISPR Therapeutics (CRSP), a top-ranked stock at present, is developing its lead pipeline candidate to treat TDT and SCD.

Here's Why You Should Add CRISPR Stock to Your Portfolio

Kala Pharmaceuticals

Ligand Pharmaceuticals

Theseus Pharmaceuticals

New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.

4 Biotech Stocks to Consider for Your Portfolio in 2023

Accuray

Illumina

Healthcare costs in America and the world are set to rise in the foreseeable future. All thanks to an aging population, and the expectation that healthcare companies will be able to cure more of our diseases.

3 Cutting-Edge Healthcare Stocks That Can Pay Off Big Time

Exelixis

2023 could be a landmark year for CRISPR Therapeutics. Exelixis has solid fundamentals, plus plenty of upside potential.

3 Beaten-Down Stocks That Could Soar This Year

ZUG, Switzerland and BOSTON, March 14, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation of preclinical data at the American Association for Cancer Research (AACR) 2023 Annual Meeting, taking place April 14 – 19, 2023, in Orlando, FL.

CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting

ZUG, Switzerland and BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announces the hiring and appointment of Raju Prasad, Ph.D., as Chief Financial Officer, effective March 14, 2023. He joins CRISPR Therapeutics from William Blair & Company, where he served as a Partner and Senior Equity Research Analyst covering cell therapy, gene therapy, and gene editing companies. Dr. Prasad succeeds Brendan Smith, who is leaving the Company to pursue external opportunities.

CRISPR Therapeutics Announces Transition of Chief Financial Officer

Novartis

Regeneron Pharmaceuticals

Verve Therapeutics

These CRISPR stocks could be big winners for patient investors.

Investing in Top CRISPR Companies

CRISPR Therapeutics is a clinical-stage biotech company. The company's pipeline includes two promising wholly owned therapies.

Missed Out on Vertex? My Best Gene-Editing Stock to Buy and Hold

Adyen NV

Caterpillar

Magna International

NVIDIA

Tesla

Investing in Cathie Wood stocks means directing your money toward innovation. And that means investing heavily in tech, a sector that has been pummeled by interest rates held higher by a Federal Reserve battling runaway inflation.

7 Cathie Wood Stocks for Your March Buy List

CRISPR Therapeutics AG (NASDAQ:CRSP ) Cowen 43rd Annual Healthcare Conference Call March 6, 2023 10:30 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Tyler Van Buren - Cowen Tyler Van Buren Good morning, everyone. Tyler Van Buren here senior biotech analyst at TD Cowen.

CRISPR Therapeutics AG (CRSP) Cowen 43rd Annual Healthcare Conference (Transcript)

The 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work on developing tools to change the genetic code of living cells, tools called CRISPR/Cas. Yet long before their trip to Stockholm, they and other scientists had been diligently founding companies to monetize this new discovery.

3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing

Moderna

Moderna's pipeline programs may drive another huge phase of growth. The potential approval of CRISPR's first product could be a major catalyst for the stock.

Better Growth Stock: Moderna vs. CRISPR Therapeutics

Institutional investors might be on to something.

3 Things About CRISPR Therapeutics That Smart Investors Know

Beam Therapeutics could be a huge winner over the long run with its base-editing therapies.

3 Game-Changing Stocks to Buy in March

Fiverr

Investors are bidding up shares of these companies, and there are good reasons for doing so.

2 Soaring Stocks to Buy and Hold Through 2023 and Beyond

Axcelis Technologies

Amazon

ARK Genomic Revolution Multi-Sector ETF

Celsius Holdings

Alphabet

QUALCOMM

Target

United Rentals

Veeva Systems

These diversified growth stocks could add rocket fuel to your long-term investment portfolio.

10 Best Stocks to Buy in March 2023

News for CRISPR Therapeutics Stock (CRSP)